Garcia-Marquez, Maria A., Shimabukuro-Vornhagen, Alexander ORCID: 0000-0002-2351-7294, Theurich, Sebastian ORCID: 0000-0001-5706-8258, Kochanek, Matthias, Weber, Tanja, Wennhold, Kerstin ORCID: 0000-0001-5539-7226, Dauben, Alexandra, Dzionek, Andrzej, Reinhard, Claudia and von Bergwelt-Baildon, Michael (2014). A multhnerized form of recombinant human CD40 ligand supports long-term activation and proliferation of B cells. Cytotherapy, 16 (11). S. 1537 - 1545. OXFORD: ELSEVIER SCI LTD. ISSN 1477-2566

Full text not available from this repository.

Abstract

Background aims. CD40-activated B cells have long been studied as potent antigen-presenting cells that can potentially be used for cancer immunotherapy. Nevertheless, their use in human clinical trials has been limited by the lack of a Good Manufacturing Practice grade soluble human CD40 ligand that is able to induce activation and proliferation of primary B cells. We describe an in vitro method to effectively generate and expand B cells through the use of a multimerized form of human recombinant CD40 ligand (rCD40L). Methods. Human B cells were isolated from healthy donors and cultivated with either rCD40L or on a monolayer of murine NIH3T3 cells stably expressing human CD40L (NIH3T3/tCD40L) as a widely used standard method. Morphology, expansion rate, immune phenotype and antigen presentation function were assessed. Results. B cells efficiently proliferated in response to rCD40L over 14 days of culture in comparable amounts to NIH3T3/ tCD40L. B-cell division in response to CD40L was also confirmed by carboxyfiuorescein succinimidyl ester dilution. Moreover, rCD40L induced on B cells upregulation of co-stimulatory molecules essential for antigen presentation. Additionally, proliferation of T cells from allogeneic healthy volunteers confirmed the immunostimulatory capacities of CD40-activated B cells. Conclusions. We demonstrated that B cells with potent antigen presentation capacity can be generated and expanded by use of a non-xenogeneic form of CD40L that could be implemented in future human clinical settings.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Garcia-Marquez, Maria A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Shimabukuro-Vornhagen, AlexanderUNSPECIFIEDorcid.org/0000-0002-2351-7294UNSPECIFIED
Theurich, SebastianUNSPECIFIEDorcid.org/0000-0001-5706-8258UNSPECIFIED
Kochanek, MatthiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weber, TanjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wennhold, KerstinUNSPECIFIEDorcid.org/0000-0001-5539-7226UNSPECIFIED
Dauben, AlexandraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dzionek, AndrzejUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Reinhard, ClaudiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
von Bergwelt-Baildon, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-424968
DOI: 10.1016/j.jcyt.2014.05.011
Journal or Publication Title: Cytotherapy
Volume: 16
Number: 11
Page Range: S. 1537 - 1545
Date: 2014
Publisher: ELSEVIER SCI LTD
Place of Publication: OXFORD
ISSN: 1477-2566
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ANTIGEN-PRESENTING CELLS; T-CELLS; DENDRITIC CELLS; LYMPHOCYTES; GENERATION; MOLECULES; SYSTEM; MODELMultiple languages
Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & ExperimentalMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/42496

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item